A
Aqemia
Using quantum-physics with AI to speed up the discovery of novel drug molecules
About Aqemia
Aqemia, a pharmatech company, was founded in 2019 by CEO Maximilien Levesque and COO Emmanuelle Martiano, as a spin-off from the École Normale Supérieure (ENS) in Paris. The company is built on 8 years of research in quantum-inspired physics.
Read full description
The company's core business is to accelerate the discovery of new drug candidates. It has developed a platform that combines quantum and statistical mechanics algorithms with artificial intelligence. This technology aims to predict the affinity between a drug candidate and a therapeutic target, thereby speeding up the drug discovery process. Aqemia's platform is used for both small molecules and biologics.
The business model of Aqemia involves forming research collaborations with pharmaceutical and biotechnology companies. In these collaborations, Aqemia leverages its platform to identify promising drug candidates for specific therapeutic targets provided by its partners. The company receives upfront payments, milestone payments based on the progress of the drug candidates, and royalties on the sales of the drugs that are successfully developed and commercialized.
Aqemia also has its own internal drug discovery pipeline, which is focused on oncology and immuno-oncology. The company is developing a portfolio of proprietary drug candidates, which it may choose to develop on its own or in partnership with other companies.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Paris, France
- Employees
- 85
- Open positions
- 8
- Dealroom signal
- 86.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Research and Development
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Machine Learning, Deep Learning, Quantum Technologies
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Apr 2025 | $7.4M | — | France 2030 | ↗ |
| EARLY VCOther financing | Dec 2024 | $40M | $158M | Elaia · Bpifrance · Eurazeo · Wendel | ↗ |
Growth signals
Latest recorded traffic for Aqemia is 2.8K monthly website visits, down 54.8% over the last three months. Aqemia's team grew 7.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Elaia
France 2030
Other known investors4 additional known investors
Agoranov
CNRS Innovation
French National Centre for Scientific Research - CNRS
PSL University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aqemia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aqemia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.